Document is current
Any future updates will be listed below
-
Authors
Jian, Fanchong https://orcid.org/0000-0001-8703-3507
Wec, Anna Z.
Feng, Leilei
Yu, Yuanling
Wang, Lei
Wang, Peng
Yu, Lingling
Wang, Jing https://orcid.org/0000-0002-9084-9985
Hou, Jacob
Berrueta, Daniela Montes
Lee, Diana
Speidel, Tessa
Ma, LingZhi
Kim, Thu https://orcid.org/0000-0002-8299-6627
Yisimayi, Ayijiang https://orcid.org/0000-0003-0648-1864
Song, Weiliang
Wang, Jing
Liu, Lu
Yang, Sijie https://orcid.org/0009-0001-9834-4340
Niu, Xiao
Xiao, Tianhe
An, Ran
Wang, Yao
Shao, Fei
Wang, Youchun https://orcid.org/0000-0001-9769-5141
Pecetta, Simone https://orcid.org/0000-0001-9898-4324
Wang, Xiangxi https://orcid.org/0000-0003-0635-278X
Walker, Laura M. https://orcid.org/0000-0001-7704-3197
Cao, Yunlong https://orcid.org/0000-0001-5918-1078
-
Funding
Funding for this research was provided by:
Ministry of Science and Technology of the People's Republic of China (2022ZD0115002)
National Natural Science Foundation of China (32222030)
- License Information
-
More Information
Article History
Received: 29 September 2024
Accepted: 8 May 2025
First Online: 10 June 2025
Competing interests
: Y.C. is listed as an inventor for provisional patent applications of SARS-CoV-2 RBD-specific antibodies involved in this study, including BD55-1205. The patent of BD55-1205 is licensed to Moderna. Y.C. is a co-founder of Singlomics Biopharmaceuticals. A.Z.W., J.H., D.M.B., D.L., T.S., L.M., T.K., S.P. and L.M.W. are full-time employees and holders of equity in Moderna Therapeutics. The other authors declare no competing interests.
